Douglas Grossman, Nwanneka Okwundu, Edmund K Bartlett, Michael A Marchetti, Megan Othus, Daniel G Coit, Rebecca I Hartman, Sancy A Leachman, Elizabeth G Berry, Larissa Korde, Sandra J Lee, Menashe Bar-Eli, Marianne Berwick, Tawnya Bowles, Elizabeth I Buchbinder, Elizabeth M Burton, Emily Y Chu, Clara Curiel-Lewandrowski, Julia A Curtis, Adil Daud, Dekker C Deacon, Laura K Ferris, Jeffrey E Gershenwald, Kenneth F Grossmann, Siwen Hu-Lieskovan, John Hyngstrom, Joanne M Jeter, Robert L Judson-Torres, Kari L Kendra, Caroline C Kim, John M Kirkwood, David H Lawson, Philip D Leming, Georgina V Long, Ashfaq A Marghoob, Janice M Mehnert, Michael E Ming, Kelly C Nelson, David Polsky, Richard A Scolyer, Eric A Smith, Vernon K Sondak, Mitchell S Stark, Jennifer A Stein, John A Thompson, John F Thompson, Suraj S Venna, Maria L Wei, Susan M Swetter
Importance: Use of prognostic gene expression profile (GEP) testing in cutaneous melanoma (CM) is rising despite a lack of endorsement as standard of care. Objective: To develop guidelines within the national Melanoma Prevention Working Group (MPWG) on integration of GEP testing into the management of patients with CM, including (1) review of published data using GEP tests, (2) definition of acceptable performance criteria, (3) current recommendations for use of GEP testing in clinical practice, and (4) considerations for future studies...
September 1, 2020: JAMA Dermatology